Meta Pixel

News and Announcements

Fintech, Nauticus, aiming for $25M equity raise

  • Published May 01, 2019 12:00AM UTC
  • Publisher Wholesale Investor
  • Categories Company Updates

Highlights

  • Nauticus is aiming for a $25 million equity raise to reach its goal of low cost, borderless financial transactions.
  • The equity raise aims to onboard 2.9 million users by 2022 and fund additional cross-platform marketing and international expansion.
  • A conservative discounted cash flow analysis values Nauticus post raise at $74.2 million.

Melbourne-based Fintech Nauticus offers 17 digital currencies and AUD with a 50, 000 strong community since its launch in 2018. They are now aiming for a $25 million equity raise to reach its goal of low cost, borderless financial transactions.

The equity raise aims to onboard 2.9 million users by 2022 and fund additional cross-platform marketing and international expansion. A conservative discounted cash flow analysis values Nauticus post raise at $74.2 million.

Nauticus draws its talent from across the globe including National Australia Bank (AUS), ANZ (AUS), Goldman Sachs (UK), Bank of Melbourne (AUS), Accenture (USA), News Corp (AUS) and Telstra (AUS), culminating in 280, 000 accounts across 84 countries. Later this year, the company will move into securities trading, FOREX and international remittances.

 

About Nauticus

Nauticus is a Melbourne based fintech company that provides user-friendly and secure crypto banking and eCommerce solutions utilizing blockchain technology, underpinned by the Nauticus Coin.

Capital Insights
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship

From the arid deserts of Australia to the boardrooms of global tech giants, SWAN Systems is redefining water efficiency. By bridging the gap between field-level agronomics and autonomous irrigation control, the company is proving that “water-positive” targets can be met with science, data, and a 10x ROI commitment.

Capital Insights
The Ferrari of Immunotherapy: Chimeric’s High-Stakes Race to Cure Cancer

In the high-stakes world of biotechnology, the most sophisticated weapon against cancer isn’t a new chemical compound but the patient’s own immune system, re-engineered with the precision of a high-performance engine. “This particular CAR T is like a Ferrari,” says Dr. Rebecca McQualter, CEO of Chimeric Therapeutics (ASX: CHM). “It’s got two big engines on […]

Capital Insights
From Algae Pioneers to a Natural Revolution: The Second Act of WRS Bioproducts

As the US FDA prepares to phase out synthetic food colors by the end of 2026, WRS Bioproducts is stepping in to solve a looming supply crisis. Led by industry pioneer Harry Rosen, the company is leveraging 40 years of industrial algae farming expertise to scale production of natural, superior-quality beta-carotene, positioning itself as a vital supplier in the rapidly shifting global market for natural ingredients.

Join over 45,000+ sophisticated investors

Join Now